2Ge J,Chirillo F,Schwedtmann J,et al.Screening of ruptured plaques in patients with coronary artery disease by intravascular ultrasound.Heart,1999,81:621-627.
3Fussl RT,Kranenberg E,Kiausch U,et al.Vascular remodeling in atherosclerotic coronary arteries is affected by plaque composition.Coron Artery Dis,2001,12:91-97.
4Libby P.Changing concepts of atherogenesis.J Intern Med,2000,247:349.
5Hassan A,Basisht R,Nakamura M,et al.Morphological characteristics of de novo coronary lesions presenting with plaque rupture:an intravascular ultrasound study.J Am Coll Cardiol,2004,43:A73.
6Nomoto K,Oguchi S,Watanabe I,et al.Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein,matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1.J Cardiol,2003,42:201-206.
7Hong MK,Lee CW,Kim YH,et al.Independent predictors of multiple vulnerable plaque in 143 patients with acute coronary syndrome:a prospective study of three-vssel intravascular ultrasound.J Am Coll Cardiol,2004,43:A73.
8Dollery CM, McEwan JR,Henney AM. Matrix metalloprotenses and cardiovascular disease[J]. Circ Res, 1995,77(5 ) : 863-868.
9Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition,Measurement and Reporting of Intravascular Ultrasound Studies(IVUS ). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents[J]. J Am Coll Cardiol, 2001,37(5 ) : 1478-1492.
10Naghavi M,Libby P,Falk E,et al. From vulnerable plaque to vulnerable patient:a call for new definition and risk assessment strategies: part Ⅰ [J]. Circulation, 2003,108 ( 14 ) : 1664-1772.
2Zhong L,Chen WQ,Ji XP,et al.Dominant-negative mutation of monocyte chemoattractant protein-1prevents vulnerable plaques from rupture in rabbits independent of serum lipid levels.J Cell Mol Med,2008,12:2362-2371.
3Ray K,Morrow D,Gibson C,et al.Predictors of the rise in vWF after ST elevation myocardial infarction:implications for treatment strategies and clinical outcome:An ENTIRE-TIMI23substudy.Eur Heart J,2005,26:440-446.
4Cavusoglu E,Ruwende C,Eng C,et al.Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome.Am J Card,2007,99:1364-1368.
5Wang WY,Zhang J,Wu WY,et al.Inhibition of lipoprotein-associated phospholipase A2ameliorates inflammation and decreases atherosclerotic plaque formation in apoE-deficient mice.PLoS One,2011,6:e23425.
6Zoccali C,Seck S.What makes plaques vulnerable in CKD?:a fresh look at metalloproteinases.Kidney Int,2010,78:1206-1208.
7Heeschen C,Dimmeler S,Hamm CW,et al.Pregnancy associated plasma prote in A levels in patients with acute coronary syndromes:comparison with markers o fsy stemic inflammation,platelet activation,and mycardial necrosis.J Am Coll Cardiol,2005,45:229-237.
